What Side Effects Are Associated with CJC-1295 and Ipamorelin?

Most reports describe mild and short-lived reactions, redness or swelling where the shot goes in, facial warmth for minutes and brief lightheadedness. The FDA flags more serious signals for CJC-1295, faster heart rate and a body-wide vessel widening reaction that can affect circulation.

What feels most common right after the shot?

The skin at the injection spot often reddens, swells or itches and then calms within 24 to 48 hours without treatment (trial summary).

Your face or upper chest may feel warm and look flushed for 10 to 30 minutes after the shot. Trial summaries link this flush to a brief widening of blood vessels triggered by CJC-1295 (trial summary). Lightheadedness or dizziness can follow the shot as well and it tends to fade after the first few doses.

Fingers, hands or feet may tingle and rings may feel tight from extra fluid. The longer-acting DAC version (drug affinity complex, a form that stays in the body longer) produces more sustained fluid and tingling effects (guide). Early studies of that longer-acting form in healthy adults reported no serious events, and injection site pain, swelling and firmness were the most common complaints (review).

What serious risks has the FDA flagged?

FDA reviewers identified serious events with CJC-1295. They include faster heart rate and a systemic vessel widening reaction. This means vessels across the body widen enough to affect blood flow (FDA safety page).

The agency also notes possible immune responses with certain routes and added complexity from peptide impurities and quality testing. It states that available clinical data are limited (FDA safety page). Reviewers added that drugs that raise the body’s own growth hormone may share risks seen with prescription growth hormone, such as pancreas inflammation and QT prolongation, a change in the timing of the heartbeat (FDA briefing).

What about the death reports?

In a Phase II trial in 192 patients with HIV-related fat changes, one person died of a heart attack about two hours after the 11th weekly shot (review). The trial enrolled a different health group on a weekly schedule, so the report shows what happened in that setting and does not show how often it would happen with other uses.

For ipamorelin, the FDA noted serious events that included death when researchers gave the peptide directly into a vein to test bowel movement after surgery. That vein route differs from the usual shot under the skin, and development for that bowel use stopped without approval (review).